Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 37Neoplasm Metastasis 6Neoplasms 3Ovarian Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms by Site 1Medulloblastoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1ER+ HER2- Advanced Breast Cancer 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fulvestrant 4serabelisib 2sapanisertib 2ribociclib 2palbociclib 2tivozanib 1pembrolizumab 1olaparib 1exemestane 1abemaciclib 1Tamoxifen 1Secretin 1STX-478 1Radiotherapy 1Pharmaceutical Preparations 1Paclitaxel 1Nivolumab 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Carboplatin 1CA-19-9 Antigen 1Anastrozole 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hereditary Sensory and Autonomic Neuropathies × ribociclib × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Totus Medicines

Phase 1 Recruiting
241 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡